Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Accumulated Expenses: 2012-2024

Historic Accumulated Expenses for CorMedix (CRMD) over the last 10 years, with Dec 2024 value amounting to $32.0 million.

  • CorMedix's Accumulated Expenses rose 542.71% to $109.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.1 million, marking a year-over-year increase of 542.71%. This contributed to the annual value of $32.0 million for FY2024, which is N/A change from last year.
  • CorMedix's Accumulated Expenses amounted to $32.0 million in FY2024, which was up 704.03% from $4.0 million recorded in FY2022.
  • CorMedix's Accumulated Expenses' 5-year high stood at $32.0 million during FY2024, with a 5-year trough of $2.9 million in FY2020.
  • Its 2-year average for Accumulated Expenses is $18.0 million, with a median of $18.0 million in 2022.
  • As far as peak fluctuations go, CorMedix's Accumulated Expenses slumped by 39.06% in 2020, and later soared by 31.84% in 2022.
  • Yearly analysis of 4 years shows CorMedix's Accumulated Expenses stood at $2.9 million in 2020, then increased by 3.07% to $3.0 million in 2021, then soared by 31.84% to $4.0 million in 2022, then reached $32.0 million in 2024.